Harlan S. Robins, the chief scientific officer of Adaptive Biotechnologies Corporation (NASDAQ:ADPT), sold 386,240 shares of common stock at $22.01 per share on July 2, 2026, according to an SEC Form 4 filing.
Transaction summary
Key questions
-
What was the mechanism for this transaction?
The sale was conducted under a Rule 10b5-1 trading plan established on March 13, 2026, which allows corporate insiders to set a predetermined schedule for selling shares to avoid potential conflicts regarding material non-public information. -
How does the transaction price compare to the current market level?
Robins sold shares at a weighted average price of $22.01, while the stock was priced at $21.50 as of the July 6, 2026, market close. -
What is the status of the insider’s remaining equity position?
After disposing of the roughly 386,000 shares, Robins continues to hold 1,019,658 shares directly, representing a post-transaction market value of $21.61 million. -
What has been the stock’s recent performance trajectory?
As of the transaction date on July 2, 2026, Adaptive Biotechnologies Corporation had generated a one-year total return of 85%.
Company Overview
Company Snapshot
-
Adaptive Biotechnologies develops and commercializes an immune medicine platform anchored by its immunoSEQ immunosequencing technology, which enables precise diagnosis and treatment of a broad spectrum of diseases through immune profiling and T-cell receptor analysis.
-
The company generates revenue through licensing its proprietary immunosequencing platform to diagnostic and therapeutic partners, conducting research collaborations, and offering clinical and research services that leverage its advanced immune profiling capabilities.
-
Adaptive Biotechnologies serves pharmaceutical companies, academic research institutions, clinical laboratories, and healthcare systems seeking to develop personalized immunotherapies and advance precision medicine approaches in oncology and immunological disorders.
Adaptive Biotechnologies is a commercial-stage biotechnology company investing heavily in research and development, as evidenced by its TTM net loss of $49.7 million. The company’s competitive advantage lies in its proprietary immunosequencing platform, which provides unparalleled insights into immune system composition and function, positioning it as a critical infrastructure provider for the emerging field of immune medicine and personalized therapeutics.